Navigation Links
GTx Announces Ostarine Improved Insulin Resistance among Elderly,Patients in a Recently Completed Phase II Clinical Trial

MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr 17, 2007 - GTx, Inc. (NASDAQ: GTXI) announced today that data from a recently conducted Phase II Ostarine(TM) clinical trial of 60 elderly men and 60 postmenopausal women revealed that insulin and glucose levels were reduced and insulin resistance was improved among subjects receiving the 3 mg dose of Ostarine compared to baseline. These observations were even more pronounced among a subset of prediabetic subjects.

Data from the Phase II clinical trial of Ostarine are being highlighted at the GTx Analyst Day meeting being held today from 11 a.m. to 2 p.m. at the Loews Regency Hotel in New York City. During the meeting, GTx also will provide information about its clinical development plans and commercialization strategy for Ostarine, the company's first-in-class selective androgen receptor modulator (SARM).

In the three month Phase II clinical trial in which patients with diabetes or obesity (BMI greater than 30) were excluded, subjects treated with Ostarine 3 mg (n=23) had on average an 11% decline in fasting blood glucose (p less than 0.001), a 17.6% reduction in insulin levels (p=0.043), and a 26.8% reduction in insulin resistance (HOMA-IR) (p=0.037), when compared to their baseline measurements. Improvements in insulin resistance were more apparent among a small subset of prediabetic (fasting blood glucose of 100 - 125 mg/dL) patients (n=5) treated with Ostarine 3 mg in whom the mean fasting blood glucose declined by 17.4%, insulin levels reduced by 29.4%, and insulin resistance decreased by 41.3%.

Improvements in insulin resistance among subjects receiving the 3 mg dose provide additional supporting evidence of the anabolic activity of Ostarine. The resulting changes in body composition (increased muscle and decreased fat) with Ostarine treatment appear to have a beneficial impact on insulin resistance. These data compare favorably with results of clinical
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/2/2015)... , March 2, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... announced public offering of common stock have exercised their ... common stock at a price to the public of ... the offering is expected to be $64.8 million, after ...
(Date:3/2/2015)... , March 2, 2015 For the past 15 years, ... per year in the U.S. alone (U.S. Census Bureau 2012). Of ... minor fender benders BUT there are quite a few where the ... intrusion, which can obstruct the seatbelt release button or occupant injury. ... in any serious accidents in their lifetime but may still be ...
(Date:3/2/2015)... -- Leading patient advocacy organization Fight Colorectal Cancer and ... One Million Strong campaign to spotlight colorectal ... funds for colorectal cancer education, research and prevention while ... living in the United States ... every day. Showing Strength for Colorectal Cancer ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3New SuperVizor, an Automobile Escape Tool, Ensures the Safety of Drivers and Passengers on the Road 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 2Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 3Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 4Advocacy Group Fight Colorectal Cancer and Bayer HealthCare Join Forces for One Million Strong 5
... , July 25, 2011 Pharmasset, Inc. (Nasdaq: ... to discovering, developing, and commercializing novel drugs to treat ... for the quarter ended June 30, 2011. ... quarter ended June 30, 2011 compared to $0.2 million ...
... VR Business Sales, Mergers & Acquisitions Charlotte, N.C. ... of Salisbury, NC.  This durable medical equipment provider specializes ... manual and power wheelchairs and scooters. "Penrod ... equipment providers I,ve seen.  The business generated a lot ...
Cached Medicine Technology:Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 2Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 3Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 4Pharmasset Reports Fiscal Third Quarter 2011 Financial Results 5
(Date:3/2/2015)... 2015 New York singer/songwriter Richie ... delivering a plenary address entitled Finding the Music ... of Healing and Recovery at this year’s National ... Executive Summit (BHES).     , With more than 300 ... been recorded by some of the biggest names ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Atlantic Information ... of AIS’s Directory of Health Plans: 2015 , ... available on the U.S. health plan market, with enrollment ... the United States. , Available as a printed ... of enrollment trends in quick-view tables and charts, as ...
(Date:3/2/2015)... March 02, 2015 In light of ... anticoagulant Xarelto (rivaroxaban) tablets, Ford & Associates ... be helpful for future users, but may come too ... from taking the drug. The FDA has now included ... Adverse Reactions on Xarelto's label. The term “cytolytic hepatitis” ...
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
Breaking Medicine News(10 mins):Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:Now Available from AIS: 12th Edition of Annual Book Containing Health Plan Enrollment Data, Contact Information 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3
... Children's Research Hospital have created a mouse model of a ... about //the gene therapy used to treat children that caused ... combined immunodeficiency (XSCID), is set into action by a mutation ... system from forming B and T lymphocytes. ...
... The manner of transmission of mosquito-borne viruses is well known; ... make an entry into the blood stream. But what happens ... of its victim. Researchers led by a Howard Hughes Medical ... point at a genetic element which helps the dengue virus ...
... study led by Volker Heussler of the Bernhard Nocht Institute ... malarial //parasite avoids the immune system by killing the liver ... that after infecting man, malarial parasites head to the liver ... was not known how the parasite avoids the immune system. ...
... gene which was identified by Professor Sir David Lane of ... gene using the mice model shows that the gene keeps ... Donehower of Baylor College of Medicine in Houston created some ... cancer. In another set he modified the gene and the ...
... Giving up your regular late-night snack may be hard, and ... change an area of the brain to expect the food// ... discovered. ,By training mice to eat at a ... turns on body-clock genes in a particular area of the ...
... isn't limited to soldiers or witnesses of a horrifying event. ... or heart surgery. Not only does PTSD cause emotional// and ... progression of heart disease, reports the August issue of the ... PTSD is that the trauma comes from within. Sufferers are ...
Cached Medicine News:Health News:Discovery In "Bubble Boy" Disease Gene Therapy 2Health News:Discovery In "Bubble Boy" Disease Gene Therapy 3Health News:Discovery In "Bubble Boy" Disease Gene Therapy 4Health News:The Dengue Virus Unplugged 2Health News:The Dengue Virus Unplugged 3Health News:Timing of Food Consumption Activates Genes in Specific Brain Area 2
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... practitioners consider the HOPE nebulizer the gold standard ... made to put everything together in one convenient ... is our #11320 Adult HOPE Kit which contains ... and pediatric aerosol mask all in one set ...
... medication nebulizers offer a spill-proof design and ... a 45° angle. All medical nebulizers are ... variety of configurations are available., ,All ... ,Portex® medication nebulizers feature consistently fine ...
Medicine Products: